Q1 2024 Financial Results
Appendix
25
Alnylam Pharmaceuticals, Inc.
Reconciliation of Selected GAAP Measures to Non-GAAP Measures
(In thousands, except per share amounts)
26 Please note that the figures presented may not sum exactly due to rounding
Alnylam Pharmaceuticals, Inc.
Reconciliation of Revenue and Growth at Constant Currency
Please note that the figures presented may not sum exactly due to rounding
27 Constant Currency = Constant Exchange Rate, or CER
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Alnylam Pharmaceuticals Inc. published this content on 02 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 May 2024 12:58:18 UTC.